14th May 2025 14:28
Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology. Read More
